FCM
KPTI icon

Frontier Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Frontier Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-41,944
Closed -$3.44M – 271
2022
Q3 		$3.44M Sell
41,944
-223
-0.5% -$16.7K 0.04% 249
2022
Q2 		$2.85M Sell
42,167
-43,119
-51% -$3.95M 0.03% 262
2022
Q1 		$9.43M Sell
85,286
-27,074
-24% -$3.37M 0.09% 215
2021
Q4 		$10.8M Buy
112,360
+38,865
+53% +$3.87M 0.09% 216
2021
Q3 		$6.42M Sell
73,495
-25,768
-26% -$2.67M 0.05% 244
2021
Q2 		$15.4M Buy
99,263
+17,821
+22% +$2.59M 0.11% 203
2021
Q1 		$12.9M Sell
81,442
-127,063
-61% -$26.8M 0.1% 204
2020
Q4 		$48.4M Sell
208,505
-38,414
-16% -$8.9M 0.36% 105
2020
Q3 		$54.1M Buy
246,919
+60,886
+33% +$14.9M 0.47% 76
2020
Q2 		$52.9M Buy
186,033
+63,404
+52% +$18.8M 0.47% 76
2020
Q1 		$35.3M Buy
122,629
+54,686
+80% +$15.1M 0.4% 92
2019
Q4 		$19.5M Sell
67,943
-50,448
-43% -$10.9M 0.14% 178
2019
Q3 		$17.1M Buy
118,391
+72,867
+160% +$9.88M 0.13% 186
2019
Q2 		$4.09M Sell
45,524
-34
-0.1% -$2.73K 0.03% 266
2019
Q1 		$3.99M Buy
45,558
+34,498
+312% +$3.82M 0.03% 270
2018
Q4 		$1.55M Sell
11,060
-2,577
-19% -$435K 0.01% 280
2018
Q3 		$3.48M Sell
13,637
-6,832
-33% -$1.89M 0.02% 272
2018
Q2 		$5.22M Buy
+20,469
New +$5.06M 0.04% 260

Other funds holding KPTI

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Frontier Capital Management's KPTI Position: Q4 2022 in Review

Frontier Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q4 2022, closing a stake of 41,944 shares — an estimated $3.44M sold.

Frontier Capital Management first reported a position in KPTI in Q2 2018 and held it in 18 quarters. The position peaked at $54.1M in Q3 2020. 154 funds tracked by Wall St. Rank hold KPTI as of Q4 2022.

  • Frontier Capital Management reported no remaining Karyopharm Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Frontier Capital Management sold 41,944 Karyopharm Therapeutics shares in Q4 2022, an estimated $3.44M.
  • Frontier Capital Management first reported a position in Karyopharm Therapeutics in Q2 2018 and held it in 18 quarters.
  • Frontier Capital Management's Karyopharm Therapeutics position peaked at $54.1M in Q3 2020.
  • 154 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2022.

Based on Frontier Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.